The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
The company shall process the change of name application with BSE Ltd. in due course
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
India plays a critical role in Bristol Myers Squibb’s global strategy
Dr Srivastava was selected by an expert jury in recognition of her sustained contributions to renewable chemicals, industrial biotechnology and bioprocess innovation
Clinical trial enrollment has long been a bottleneck in drug development
Updated results from the EMBER-3 study showed that the drug -- Inluriyo (imlunestrant) -- as a standalone treatment cut the risk of progression or death by 38%
The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA
Subscribe To Our Newsletter & Stay Updated
